NCT07023848View on ClinicalTrials.gov

PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors

EARLY_PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

July 7, 2026

Study Completion Date

December 1, 2026

Conditions
Breast CancerGastric Cancer (GC)Urothelial Carcinoma (UC)
Interventions
DRUG

89Zr-LNCab104

89Zr-LNCab104 is administered through a superficial dorsal vein, and the patient is given a dose of about 1-3 mCi

DRUG

89Zr-LNCab103

89Zr-LNCab103 is administered through a superficial dorsal vein, and the patient is given a dose of about 1-3 mCi

DRUG

18F-FDG

18F-FDG is administered through a superficial dorsal vein, and the patient is given a dose of about 0.1-0.15mCi/kg.

Trial Locations (1)

214000

Affiliated Hospital of Jiangnan University, Wuxi

All Listed Sponsors
lead

Affiliated Hospital of Jiangnan University

OTHER